| *GENE.00059 Hybrid Personalized Molecular Residual Disease Testing for Cancer |
Oncologic hybrid personalized molecular residual disease (MRD) tests are considered INV & NMN for all indications No specific code currently for this test, considered INV & NMN; listed 81479 NOC |
12/1/2022 |
| * LAB.00048 Pain Management Biomarker Analysis |
The functional pain biomarker urine test panel is considered INV & NMN for chronic pain management and for all other indications Listed existing CPT® PLA code 0117U specific to this test; considered INV & NMN |
12/1/2022 |
Source: https://providernews.anthem.com/ohio/article/medical-policy-and-clinical-guideline-updates-september-2022-1
